Organic Pressurized Fluid Patents (Class 424/45)
  • Patent number: 9795564
    Abstract: A waterless foamable carrier and pharmaceutical composition which is suitable for external and internal administration is disclosed. The composition is single phase and includes at least one liquid oil; and a glyceride. Pharmaceutical compositions comprising active agents, methods for their preparation, propellants suitable for use with the carriers and uses thereof are further described.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: October 24, 2017
    Assignee: FOAMIX PHARMACEUTICALS LTD.
    Inventors: Dov Tamarkin, David Schuz, Yohan Hazot, Elana Gazal
  • Patent number: 9789123
    Abstract: Stable pharmaceutical compositions and processes for making same for the treatment of psoriasis. The compositions may be nanoemulsions having nano size droplets of one or more anti-psoriasis agents, e.g. clobetasol and/or salicylic acid. The compositions exhibit improved permeability and bioavailability.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: October 17, 2017
    Assignee: Cadila Healthcare Limited
    Inventors: Sunilendu Bhushan Roy, Jay Shantilal Kothari, Shafiq Sheikh, Jitendra Dasharathlal Patel, Jinesh Suresh Pancholi
  • Patent number: 9777123
    Abstract: Low molecular weight sulfated beta-O4 lignin (SbO4L) are potent inhibitors of coagulation with high selectivity.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: October 3, 2017
    Assignee: Virginia Commonwealth University
    Inventors: Umesh R. Desai, Jay Thakkar, Akul Mehta
  • Patent number: 9757337
    Abstract: The present invention relates to novel multicompartmental lipid nanoparticles (or cellisomes) with excellent stability comprising a first lipophilic compartment (lipid matrix) partly anchored to a second hydrophilic compartment delimited by a phospholipid bilayer (bilayer), as well as the method for preparing same and the use thereof as a vector for administering a wide variety of molecules of interest.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: September 12, 2017
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, UNIVERSITE PARIS-SUD
    Inventors: Vincent Faivre, Sylviane Lesieur, Michel Ollivon, Modibo Ouattara, Tri Truong Cong
  • Patent number: 9750786
    Abstract: An interferon composition is provided for enhancing the platelet count, reducing the recurrence rate of hepatitis, and/or improving the social function of hepatitis patients. The method comprises administering a low dose of IFN (about 5 IU to about 2500 IU of IFN-alpha) to a patient in need thereof. In one embodiment the IFN is alpha IFN or beta IFN, and more particularly, in one embodiment the administered biologically active IFN is human alpha IFN.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: September 5, 2017
    Assignee: Amarillo Biosciences, Inc.
    Inventors: Martin Joseph Cummins, Chau-Ting Yeh, Ching-Yuan Lee
  • Patent number: 9737481
    Abstract: A foamable pharmaceutical composition and a method of treating corticosteroid-responsive dermatoses of the skin are disclosed. The foamable pharmaceutical composition comprises a corticosteroid compound as an active ingredient; a quick-break foaming agent including an aliphatic alcohol, water, a fatty alcohol and a surface active agent; a buffering agent; and a propellant. The foamable composition is disposed within a pressurizable container that comprises an aerosol valve assembly including a dip tube communicating with a valve orifice through which the foamable composition is dispensed and an actuator to start and stop dispensation. The valve assembly dispenses a conically-shaped spray at a rate of about 2 to about 0.3 g/sec and provides a foam having a density of about 0.12 to about 0.25 when sprayed at a distance of about 5 to about 10 cm from the valve orifice onto a glass surface that is at ambient room temperature.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: August 22, 2017
    Assignee: Delcor Assett Corporation
    Inventors: Michael V. Lowenborg, Kuljit Bhatia
  • Patent number: 9724382
    Abstract: The invention relates to liquid pharmaceutical compositions containing: a) a therapeutically effective dose of a cyclosporin; b) an aqueous carrier liquid; c) a first solubilizing substance selected among the group of phospholipids; and d) a second solubilizing substance selected among the group of non-ionic surfactants. Preferably, the cyclosporin is liposome solubilized. The inventive composition is suitable for oral, parenteral, nasal, mucosal, topical, and particularly pulmonary application in the form of an aerosol.
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: August 8, 2017
    Assignee: PARI Pharma GMBH
    Inventors: Manfred Keller, Aslihan Akkar, Ralf Mehrwald
  • Patent number: 9724324
    Abstract: Topical alcohol-free thermo labile oily foam composition comprising (i) at least one active pharmaceutical ingredient or ectoparasitic active ingredient; (ii) at least about 20% w/w of at least one lipophilic component; (iii) at least about 10% w/w of at least one non-ionic surfactant; (iv) at least about 0.5% w/w of at least one fatty alcohol or fatty acid or ester thereof with melting point above 30° C., and; (v) at least about 7% w/w of propellant selected from propane, butane, isobutane and combinations thereof; said composition optionally comprising at least about 5% to about 70% w/w of a hydrophilic component, optionally comprising up to about 5% w/w hydrogenated oil and optionally comprising a penetration enhancer.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: August 8, 2017
    Assignee: PERRIGO ISRAEL PHARMACEUTICALS LTD.
    Inventors: Michal N. Arnon, Tatiana Kamenetsky
  • Patent number: 9662298
    Abstract: Unique foamable vehicles or carriers comprising at least one wax, waxy substance, counterpart or derivative, a stabilizer, water, and a propellant are provided. In some embodiments, the wax is a liquid wax. In some embodiments, the wax includes a solid wax and a liquid wax. The compositions are substantially free of crystals. The components are selected to provide a composition that is substantially resistant to aging and to phase separation, and/or can substantially solubilize and or stabilize active ingredients. Pharmaceutical and cosmetic compositions with potentially enhanced skin delivery and their uses are also provided.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: May 30, 2017
    Assignee: FOAMIX PHARMACEUTICALS LTD.
    Inventors: Dov Tamarkin, Rita Keynan, David Schuz, Tal Berman
  • Patent number: 9655890
    Abstract: An inhalable composition comprising: nicotine or a pharmaceutically acceptable derivative or salt thereof; a propellant; a monohydric alcohol; and a glycol and/or glycol ether, characterized in that the ratio of monohydric alcohol:glycol or glycol ether by weight is from 6:1 to 1:1.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: May 23, 2017
    Assignee: Kind Consumer Limited
    Inventors: Alex Hearn, Stuart Bhimsen Lowe, Ritika Gupta, Chris Moyses
  • Patent number: 9655969
    Abstract: This invention relates to a solution formulation containing a tiotropium salt, 12-20% ethanol, 0.1-1.5% of water, 0.05-0.10% citric acid (or other organic acid) and an HFA propellant, wherein the percentages are percentages by weight based on the total weight of the formulation. The invention also provides a pMDI comprising a canister containing the formulation.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: May 23, 2017
    Assignee: Teva Branded Pharmaceutical Products R&D, Inc.
    Inventor: Xian-Ming Zeng
  • Patent number: 9637807
    Abstract: A method of preparing metal nanoparticles using an extract of desert truffles (Terfeziaceae) includes providing an aqueous solution including a metal salt; and combining an extract of Terfeziaceae with the aqueous metal salt solution to produce the metal nanoparticles. The metal salt can be silver nitrate (AgNO3) and the metal nanoparticles can be silver nanoparticles. The metal nanoparticles can have a mean diameter in the range of from about 5 nm to about 100 nm. The silver nanoparticles can be used as an antimicrobial agent and/or an anti-parasitic agent.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: May 2, 2017
    Assignee: KING SAUD UNIVERSITY
    Inventors: Manal Ahmed Gasmelseed Awad, Ebtesam Mohammed Al Olayan, Sarah Saleh Abdulla Alsaif, Muzzammil Iqbal Siddiqui, Manal Fawzy Elkhadragy
  • Patent number: 9637740
    Abstract: Described herein are methods of inhibiting mitosis, treating cancer and/or treating immune disorders through the use of agents that inhibit FAT 10 and/or the FAT 10 pathway.
    Type: Grant
    Filed: April 2, 2013
    Date of Patent: May 2, 2017
    Assignee: President and Fellows of Harvard College
    Inventors: Yifat Merbl, Marc W. Kirschner
  • Patent number: 9616070
    Abstract: GABAA receptor mediated hypersomnia can be treated by administering a GABAA receptor antagonist (e.g., flumazenil; clarithromycin; picrotoxin; bicuculline; cicutoxin; and oenanthotoxin). In some embodiments, the GABAA receptor antagonist is flumazenil or clarithromycin. The GABAA receptor mediated hypersomnia includes shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome, narcolepsy, excessive sleepiness, hypersomnia (e.g., idiopathic hypersomnia; recurrent hypersonmia; endozepine related recurrent stupor; and amphetamine resistant hypersonmia), and excessive sleepiness associated with shift work sleep disorder, obstructive sleep apnea/hypopnea syndrome, and hypersomnia (e.g., idiopathic hypersomnia; recurrent hypersomnia; endozepine related recurrent stupor; and amphetamine resistant hypersomnia.
    Type: Grant
    Filed: March 12, 2009
    Date of Patent: April 11, 2017
    Assignee: Emory University
    Inventors: Kathy P. Parker, David B. Rye, Andrew Jenkins
  • Patent number: 9592305
    Abstract: The disclosure describes nanocarried and/or microcarried jasmonate compounds and their pharmaceutical compositions, as well as use thereof for treating or preventing angiogenesis-related or NF-?B-related disorders. Also disclosed are methods of making the nanocarried and/or microcarried compounds and their compositions.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: March 14, 2017
    Assignee: Nanocare Technologies, Inc.
    Inventor: José E. Fehr Pereira Lopes
  • Patent number: 9585839
    Abstract: The invention provides a method of making a composition for inhalation which includes the step of mixing particles of additive material having a diameter of not more than 2 ?m with active particles, wherein the additive material is suitable for promoting the dispersal of active particles upon aerolization of a dry powder in a dry powder inhaler.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: March 7, 2017
    Assignee: VECTURA LIMITED
    Inventors: John Nicholas Staniforth, David Alexander Vodden Morton
  • Patent number: 9585867
    Abstract: A method of humanely incapacitating or immobilizing a human or animal by providing a formulation including a cannabinoid rendering a recipient incapacitated or immobilized within a short period of time, and a delivery system which doses the recipient with the formulation resulting in a tetrahydrocannabinol blood level of above at least approximately 1-250 milligrams per milliliter of whole blood for incapacitation, or at least approximately 250-500 milligrams per milliliter of whole blood for immobilization, and below a dosage which causes irreparable harm to or the death of the recipient. Providing a delivery system to induce an incapacitating or immobilizing dose of the formulation at a distance. Providing a formulation including an antipsychotic to prevent or mitigate any violent psychosis of the recipient. Providing the formulation which induces a lethal cannabinoid blood level in the recipient which causes the death of the recipient within a humane period of time after formulation administration.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: March 7, 2017
    Inventor: Charles Everett Ankner
  • Patent number: 9566239
    Abstract: A powder for use in a dry powder inhaler comprises: i) a fraction of fine particle size constituted by a mixture of physiologically acceptable excipient and an additive; ii) a fraction of coarse particles; and iii) at least one active ingredient. The powder is suitable for efficacious delivery of active ingredients into the low respiratory tract of patients suffering from pulmonary diseases such as asthma. In particular, the invention provides a formulation to be administered as dry powder for inhalation which is freely flowable, can be produced in a simple way, is physically and chemically stable and capable of delivering accurate doses and/or high fine particle fraction of low strength active ingredients by using a high- or medium resistance device.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: February 14, 2017
    Assignee: VECTURA LIMITED
    Inventors: John Nicholas Staniforth, David Alexander Vodden Morton, Rajbir Gill, Gaetano Brambilla, Rossella Musa, Lorenzo Ferrarini
  • Patent number: 9566234
    Abstract: Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: February 14, 2017
    Assignee: Insmed Incorporated
    Inventors: Walter Perkins, Vladimir Malinin, Xingong Li, Brian Miller, Dominique Seidel, Philipp Holzmann, Harald Schulz, Michael Hahn
  • Patent number: 9554992
    Abstract: Microparticles comprising a combination of an anticholinergic, a beta2-adrenoceptor agonist, and an inhaled corticosteroid are useful for the prevention and/or treatment of respiratory diseases.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: January 31, 2017
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Gaetano Brambilla, Michele Miozzi, Timothy J Rouse
  • Patent number: 9546145
    Abstract: An agent for enhancing therapeutic or prophylactic effect of a renin-angiotensin system inhibitor on renal diseases is disclosed, including a specific prostaglandin I derivative such as beraprost sodium as an effective ingredient.
    Type: Grant
    Filed: March 12, 2009
    Date of Patent: January 17, 2017
    Assignee: Toray Industries, Inc.
    Inventors: Hajimu Kurumatani, Mitsutaka Tamura
  • Patent number: 9533053
    Abstract: The present invention is an ophthalmic composition containing a relatively high concentration of olopatadine. The composition is typically an ophthalmic aqueous solution containing relatively high concentrations of olopatadine solubilized within the solution. The composition is preferably capable of providing enhanced relief from symptoms of ocular allergic conjunctivitis, particularly late phase symptoms of ocular allergic conjunctivitis.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: January 3, 2017
    Assignee: Alcon Research, Ltd.
    Inventors: Daniel A. Gamache, Laman Alani, Malay Ghosh, Francisco Javier Galan, Nuria Carreras Perdiguer, Onkar N. Singh
  • Patent number: 9517204
    Abstract: The present invention relates to a powder formulation which reduces side effect risk of a medicine having a side effect of drug-induced photodermatosis and increases therapeutic effect, and relates to the method for producing the same. Said powder formulation makes inhalation therapy possible by carrying out aerosolization easily, and since pharmacological effect in lung local part is increased, it is possible to decrease the dose. Skin transmigration of said medicine is controlled by a lung specific delivery technology, and photodermatosis which is a side effect can be controlled.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: December 13, 2016
    Assignees: SHIONOGI & CO., LTD., SHIZUOKA PREFECTURAL UNIVERSITIES CORPORATION
    Inventors: Satomi Onoue, Shizuo Yamada
  • Patent number: 9511144
    Abstract: A cosmetic composition suitable for topical application is provided. In some examples, the cosmetic composition can include glycerin, hexyldecanol, a vitamin B compound, and one or more materials selected from the group consisting of 1,2-pentanediol, 1,4-pentanediol, 2,4-pentanediol, 1,5-pentanediol, 1,2-butanediol, 1,3-butanediol, 1,4-butanediol, 2,3-butanediol, 1,2-hexanediol, 1,5-hexanediol, 1,6-hexanediol, 2,5-hexanediol, hexylene glycol, and combinations thereof.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: December 6, 2016
    Assignee: The Proctor & Gamble Company
    Inventors: Stevan David Jones, Kunal Virendra Gujraty, Naohisa Yoshimi, Monalisha Paul, James Terence Wescott
  • Patent number: 9486394
    Abstract: The present invention provides various pharmaceutically active topical delivery compositions. In particular, compositions of the present invention are present in a pressurized container comprising a quick-breaking alcoholic foaming agent, such that when the composition is released, i.e., dispensed, from the pressurized container, a quick-breaking temperature sensitive foam is formed. In addition, the present invention provides various aspects related to such compositions, including methods for modulating a foam characteristic, methods for improving the shelf-life of a pharmaceutically active compound, methods for the percutaneous treatment of various diseases, infections, and illnesses, and methods for evaluating foam characteristics.
    Type: Grant
    Filed: October 14, 2013
    Date of Patent: November 8, 2016
    Assignee: STIEFEL WEST COAST, LLC
    Inventors: Albert Zorko Abram, Lilian Fuchshuber
  • Patent number: 9474729
    Abstract: The invention includes a method of treating a mammal comprising topically applying an aqueous composition to a target site on the mammal, wherein the aqueous composition comprises: active ingredients comprising i) a cosmetic dye selected from a violet, blue or green dye, or combinations thereof, and ii) an enhancing ingredient, wherein the relative weight percentage of the cosmetic dye to the enhancing ingredient is about 1:2 to about 40:1, wherein the cosmetic dye interacts with keratinous material thereby i) substantially staining the target site and ii) inhibiting the active ingredients from significantly leaching from the target site.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: October 25, 2016
    Assignee: HYDROMER, INC.
    Inventors: Irina Grigorian, Manfred F. Dyck, Rainer Gruening
  • Patent number: 9468590
    Abstract: The invention relates to a foam formulation comprising a substantially emulsifier-free emulsion of the oil-in-water type, comprising an oil phase and an aqueous phase, the emulsion comprising at least one surface active, ionic polymer with a molecular weight of more than 5000 g/mol, wherein the ionic polymer is a copolymer comprising as monomer units an ionic monomer (M1) and at least one further monomer.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: October 18, 2016
    Assignee: NEUBOURG SKIN CARE GMBH & CO. KG
    Inventor: Rolf Daniels
  • Patent number: 9456978
    Abstract: The present invention is directed towards a composition comprising, in a cosmetically acceptable carrier, at least one silicone-organic polymer hybrid compound; at least one nonionic film forming polymer; at least one amphoteric film forming polymer; and a neutralizer. The present invention also relates to methods for imparting shape to or maintaining the shape of hair wherein the composition provides style memory, strong hold and good shine, while at the same time, providing smoothness and a natural feel to the hair.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: October 4, 2016
    Assignee: L'OREAL
    Inventors: Aziza Suleiman, Clarissa Nogueira
  • Patent number: 9452173
    Abstract: The present invention relates to improved topical gel compositions comprising an active agent, and uses thereof.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: September 27, 2016
    Assignee: MERZ PHARMACEUTICALS, LLC
    Inventors: Bhushan Hardas, Donna Dalton, Petra Scheppler, Anja Buch, Peter Boderke
  • Patent number: 9446131
    Abstract: The present invention relates to improved topical gel compositions comprising an active agent, and uses thereof.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: September 20, 2016
    Assignee: MERZ PHARMACEUTICALS, LLC
    Inventors: Bhushan Hardas, Donna Dalton, Petra Scheppler, Anja Buch, Peter Boderke
  • Patent number: 9447027
    Abstract: This document relates to compounds useful for treating cardiac arrhythmias, for example, long QT syndrome. Also provided herein are methods and materials for using such compounds to shorten myocardial repolarization time in a patient.
    Type: Grant
    Filed: October 20, 2011
    Date of Patent: September 20, 2016
    Assignee: The General Hospital Corporation
    Inventors: David J. Milan, David S. Peal
  • Patent number: 9422327
    Abstract: The invention relates to a novel process for preparing crystalline ciclesonide with an advantageous particle size and to the use for producing pharmaceutical preparations, in particular for topical use. The crystalline ciclesonide obtained by the novel process has advantageous aerodynamic properties, and can be further processed to inhalable or nasally administered pharmaceutical preparations without further mechanical micronization.
    Type: Grant
    Filed: March 26, 2004
    Date of Patent: August 23, 2016
    Assignee: TAKEDA GMBH
    Inventor: Beate Schmidt
  • Patent number: 9421166
    Abstract: The present invention is directed to the administration of aminoglycosides. In particular, the present invention is directed to compositions and methods for the pulmonary administration of aminoglycosides. According to a preferred embodiment, compositions and methods are provided for the localized treatment of respiratory infections.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: August 23, 2016
    Assignee: Novartis AG
    Inventors: Thomas E Tarara, Jeffry G Weers, Maria Geraldine Venthoye
  • Patent number: 9402932
    Abstract: An in situ film-forming sprayable methyl acetate-based solution of at least one absorbable, low-crystallinity, segmented copolymer contains at least one bioactive agent, which exhibits antimicrobial, anti-inflammatory, antiviral, anesthetic, hemostatic, and/or antineoplastic activity. The absorbable polymers can be a polyaxial copolyester, polyether-ester and polyether-ester urethane and the bioactive solution thereof can be applied onto animal and human skin or accessible body cavities to prevent or treat one or more disorder susceptible to the bioactive agent therein.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: August 2, 2016
    Assignee: Poly-Med, Inc.
    Inventors: Shalaby W. Shalaby, Joel T. Corbett, Jason Olbrich
  • Patent number: 9404927
    Abstract: Embodiments of the invention provide a method detecting and treating cancer, such as lung cancer. In some aspects, the method may include detecting cancer in a subject, which may comprise assessing the expression of a marker in a sample from the subject. For example, the marker may comprise c-Met and/or Fn14. In some embodiments, if the subject is diagnosed as having cancer, the method may further provide administering a therapeutically effective amount of a substance that reduces the expression level of Fn14 to the subject to reduce the invasive and migratory capabilities of the cancer.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: August 2, 2016
    Assignee: The Translational Genomics Research Institute
    Inventors: Timothy G. Whitsett, Nhan L. Tran
  • Patent number: 9382362
    Abstract: A process for manufacturing a fluoropolymer hybrid organic/inorganic composite comprising: (i) mixing at least one fluoropolymer comprising recurring units derived from at least one (meth)acrylic monomer [monomer (MA)] of formula: at least one metal compound [compound (M)] of formula: X4-mAYm, wherein each of R1, R2, R3, equal or different from each other, is independently a hydrogen atom or a C1-C3 hydrocarbon group, and ROH is a hydrogen atom or a C1-C5 hydrocarbon moiety comprising at least one hydroxyl group [polymer (F)]; wherein m is an integer from 1 to 4, A is a metal selected from the group consisting of Si, Ti and Zr, Y is a hydrolysable group, X is a hydrocarbon group comprising one or more functional groups; (ii) reacting at least a fraction of hydroxyl groups of the ROH groups of said monomer (MA) of said polymer (F) with at least a fraction of said compound (M), to obtain a grafted polymer comprising pendant —Ym-1AX4-m groups, with m, Y, A and X having same meaning as above; and (iii) hy
    Type: Grant
    Filed: March 31, 2011
    Date of Patent: July 5, 2016
    Assignee: SOLVAY SPECIALTY POLYMERS ITALY S.PA.
    Inventors: Julio A. Abusleme, Riccardo Pieri, Ivan Pagin
  • Patent number: 9370487
    Abstract: Described herein are high oil-content emulsions and compositions for the treatment of inflammatory skin disorders. The emulsions may be formulated as aerosol compositions. The aerosol propellant may be a hydrofluoroalkane propellant. The emulsions or compositions may comprise active agents, such as corticosteroids. Also described are methods of treating inflammatory skin disorders, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive emulsion or aerosol composition.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: June 21, 2016
    Assignee: Precision Dermatology, Inc.
    Inventors: Ronald M. Gurge, Mark W. Trumbore, Lisa Chin, Poonam S. Hirani
  • Patent number: 9351922
    Abstract: The present invention relates to a composition that provides for skin pigment correction comprising: zinc oxide; octinoxate; ?-arbutin; ascorbic acid; glycyrrhiza glabra extract; green tea extract; pomegranate extract; cucumber extract; niacinamide; and a carrier. The composition can be used to treat a variety of pigment issues including lentigo, liver spots, melasma, post-inflammatory pigment issues, sun spots, freckles, and age spots.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: May 31, 2016
    Inventor: Thomas Christopher Balshi
  • Patent number: 9345666
    Abstract: A foamable pharmaceutical composition and a method of treating corticosteroid-responsive dermatoses of the skin are disclosed. The foamable pharmaceutical composition comprises a corticosteroid compound as an active ingredient; a quick-break foaming agent including an aliphatic alcohol, water, a fatty alcohol and a surface active agent; a buffering agent; and a propellant. The foamable composition is disposed within a pressurizable container that comprises an aerosol valve assembly including a dip tube communicating with a valve orifice through which the foamable composition is dispensed and an actuator to start and stop dispensation. The valve assembly dispenses a conically-shaped spray at a rate of about 2 to about 0.3 g/sec and provides a foam having a density of about 0.12 to about 0.25 when sprayed at a distance of about 5 to about 10 cm from the valve orifice onto a glass surface that is at ambient room temperature.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: May 24, 2016
    Assignee: Delcor Asset Corporation
    Inventors: Michael V. Lowenborg, Kuljit Bhatia
  • Patent number: 9345663
    Abstract: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: May 24, 2016
    Assignee: Gilead Sciences, Inc.
    Inventor: Alan B. Montgomery
  • Patent number: 9339463
    Abstract: Novel compositions, formulations and dosage forms comprising stabilized micronized opioid particles are disclosed. Exemplary opioids include oxycodone, oxymorphone, hydrocodone, and hydromorphone, including as free bases or as salts. Stabilized micronized opioid particles having a Dv90 particle size distribution of less and or equal to 10? or less than or equal to 20? are disclosed. Methods for micronizing an opioid to provide stabilized micronized opioid particles are also disclosed.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: May 17, 2016
    Inventors: Michael Zamloot, Cherng-chyi Fu, De-Hwa Chao, Andrei Blasko, Su Il Yum
  • Patent number: 9326929
    Abstract: A non-pressurized container that contains one or more of: a foamable composition of minoxidil, or a pharmaceutically acceptable salt thereof, and a dihydrotestosterone blocker in a formulation with a precise density and viscosity to yield a foam with a temperature sensitivity and shear strength designed for inverted application and immediate targeted release at body temperature under a minimal hand applied pressure to the scalp.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: May 3, 2016
    Inventor: Nyangenya Maniga
  • Patent number: 9308208
    Abstract: A method and device are provided to generate an aerosol having a desired particle sizes, i.e., from molecular to about 10 microns, which can be used to effectively deliver a physiologically active compound to organs and tissues such as the lung, eye, mucosa and skin. The aerosol is formed through vaporization of the compound while mixing the resulting vapor with a gas, in a ratio, to form the desired particle size when a stable concentration of particles in the gas is reached.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: April 12, 2016
    Assignee: ALEXZA PHARMACEUTICALS, INC.
    Inventors: Martin J. Wensley, Daniel Mufson, Craig C. Hodges, Peter M. Lloyd, Daniel D. Rogers
  • Patent number: 9308162
    Abstract: The present invention relates to biocompatible oligomer-polymer compositions for the in situ formation of implants, wherein the implants release a bioactive agent, a metabolite, or a prodrug thereof, at a controlled rate. The sustained release delivery system includes a flowable composition containing a bioactive agent, a metabolite, or a prodrug thereof, and an implant containing a bioactive agent, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, a biocompatible end-capped oligomeric liquid, and a bioactive agent, a metabolite, or a prodrug thereof.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: April 12, 2016
    Assignee: Tolmar Therapeutics, Inc.
    Inventor: Richard L. Norton
  • Patent number: 9301930
    Abstract: A refreshment towel with applied solution is an apparatus consisting of a carrying agent, most likely a high quality cotton towel or towelette, that has been saturated with an aqueous solution comprised of various ingredients. The resulting saturated towel can be rubbed on a user's skin such that the aqueous solution that has been absorbed by the towel is transferred. The aqueous solution is compounded specifically to provide cooling, insect repellant, sun protection, freshness, cleansing and other uses. More specifically, the aqueous solution is specially formulated so that desired sensory results take place when the towel comes in contact with the skin.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: April 5, 2016
    Inventors: A Jeffrey Whitmire, Mona L Whitmire
  • Patent number: 9295645
    Abstract: This disclosure relates to a buprenorphine sustained release delivery system for treatment of conditions ameliorated by buprenorphine compounds. The sustained release delivery system includes a flowable composition containing a suspension of buprenorphine, a metabolite, or a prodrug thereof.
    Type: Grant
    Filed: June 6, 2011
    Date of Patent: March 29, 2016
    Assignee: Indivior UK Limited
    Inventors: Richard L. Norton, Mingxing Zhou
  • Patent number: 9295644
    Abstract: The present invention relates to use of a composition for symptomatic relief, when needed, comprising, in admixture (a) a first active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate thereof or a solvate of such a salt; and (b) a second active ingredient which is budesonide; for the manufacture of a medicament for use in the prevention or treatment of an acute condition of asthma and/or intermittent asthma and/or episodes in chronic asthma. The invention further relates to a method for prevention or treatment of an acute condition of asthma and/or intermittent asthma and/or episodes in chronic asthma by administering, by inhalation, a composition comprising the first and second active ingredients as defined previously.
    Type: Grant
    Filed: September 19, 2003
    Date of Patent: March 29, 2016
    Assignee: AstraZeneca AB
    Inventor: Tommy Ekström
  • Patent number: 9283219
    Abstract: The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: March 15, 2016
    Assignee: Cynapsus Therapeutics, Inc.
    Inventors: Nathan John Bryson, Anthony John Giovinazzo, Scott David Barnhart, Michael Clinton Koons
  • Patent number: 9265726
    Abstract: The present subject matter provides foamable suspension gels that foam after release from a container. The foamable suspension gels contain at least one pharmaceutically active agent that is sparingly soluble to insoluble in water, a second pharmaceutically active agent, and optionally a third active agent.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: February 23, 2016
    Assignee: STIEFEL RESEARCH AUSTRALIA PTY LTD
    Inventors: Albert Zorko Abram, Lilian Fuchshuber
  • Patent number: 9265721
    Abstract: A composition for topical application to a part of the body comprises a local anaesthetic and optionally a vasodilator as active ingredient dissolved in a blend of volatile and non-volatile solvents of different solvating capacities for the active ingredient. The vasodilator may comprise glyceryl trinitrate and the local anaesthetic may comprises an anaesthetic of the aminoamide or aminoester type. The volatile solvent may comprise a mixture of water with a C1-C5 alcohol and the non-volatile solvent may comprise a polyhydric alcohol and optionally a glycol. A low-concentration vasodilator-containing composition is also described. The compositions allow a “virtual injection” of the active ingredient to be delivered transdermally without general systemic uptake.
    Type: Grant
    Filed: January 23, 2007
    Date of Patent: February 23, 2016
    Assignee: FUTURA MEDICAL DEVELOPMENTS LIMITED
    Inventor: Adrian Francis Davis